Compare HRTG & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRTG | ABUS |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 898.0M | 929.6M |
| IPO Year | 2014 | 2008 |
| Metric | HRTG | ABUS |
|---|---|---|
| Price | $22.03 | $4.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $33.50 | $5.00 |
| AVG Volume (30 Days) | 245.9K | ★ 1.9M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 214.43 | 55.26 |
| EPS | ★ 6.32 | N/A |
| Revenue | ★ $847,330,000.00 | $14,083,000.00 |
| Revenue This Year | $7.50 | N/A |
| Revenue Next Year | $6.74 | $239.71 |
| P/E Ratio | $4.45 | ★ N/A |
| Revenue Growth | 3.71 | ★ 128.21 |
| 52 Week Low | $16.83 | $3.04 |
| 52 Week High | $31.98 | $5.10 |
| Indicator | HRTG | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 26.83 | 48.45 |
| Support Level | $20.26 | $4.17 |
| Resistance Level | $22.79 | $4.64 |
| Average True Range (ATR) | 1.31 | 0.17 |
| MACD | -0.47 | 0.01 |
| Stochastic Oscillator | 12.38 | 50.81 |
Heritage Insurance Holdings Inc is a regional property and casualty insurance company that offers a variety of personal and commercial insurance products. Through its subsidiaries, Heritage Property & Casualty Insurance, Narragansett Bay Insurance, and Zephyr Insurance, the company issues personal residential property insurance in various states in the United States. It also offers commercial residential insurance predominantly for its Florida properties. Heritage Insurance manages insurance underwriting, customer services, actuarial analysis, distribution, and claims processing internally. Company operates in Alabama, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Maryland, Massachusetts, Mississippi, New Jersey, New York, North Carolina, Rhode Island, South Carolina.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.